Physician profile
Kathryn Ruste Chan
NPI 1588698369
$10,982.83
in general payments reported to CMS, 2019-2025
56 companies · $2,453 in 2025
The $2,453 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $644 · 2021: $1,507 · 2022: $2,015 · 2023: $2,117 · 2024: $1,566 · 2025: $2,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,230 · Long Term Medical Supply Or Device Loan: $798 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,230.49 |
| Long Term Medical Supply Or Device Loan | $797.60 |
| Education | $108.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,851.86 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,316.87 | 2019-2025 | Opdualag, Opdivo, Reblozyl |
| Janssen Biotech, INC. | $789.69 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Astrazeneca Pharmaceuticals LP | $770.42 | 2020-2025 | Lynparza, Imfinzi, Enhertu |
| Seagen INC. | $553.49 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Exelixis INC. | $395.37 | 2019-2025 | Cabometyx |
| Celgene Corporation | $373.79 | 2019-2025 | Reblozyl, Opdualag |
| Amgen INC. | $369.60 | 2020-2023 | Lumakras, Kyprolis |
| Abbvie INC. | $326.38 | 2021-2025 | Venclexta |
| Pfizer INC. | $275.32 | 2019-2025 | |
| Incyte Corporation | $263.40 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $254.00 | 2019-2025 | Keytruda, Welireg |
| Eisai INC. | $215.68 | 2019-2025 | |
| Genentech USA, INC. | $210.54 | 2019-2024 | Venclexta, Phesgo, Perjeta |
| Kite Pharma, INC. | $201.16 | 2021-2025 | Yescarta |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.